Podcasts about lantheus

“If you can image it, if you can light it up, then you know where it’s going to go,” Lantheus’ CEO Brian Markison says as he explains the future of imaging agents to Bloomberg Intelligence. “You know it’s going to get to the tumor, and then if you can attach basically a warhead to it, then you can deliver targeted radiation to that tumor.” In this episode of the Vanguards of Health Care podcast, Markison sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview to discuss how the Pylarify and Definity imaging agents enhance disease detection compared with traditional imaging platforms. They also dive into the importance of manufacturing and logistics to get the agents to the right hospital at the right time and the future pipeline with a portfolio of agents under development to detect Alzheimer’s and neuroendocrine tumors.See omnystudio.com/listener for privacy information.

► Get a free share!This show is sponsored by Trading 212! To get free fractional shares worth up to 100 EUR / GBP, you can open an account with Trading 212 through this link https://www.trading212.com/Jdsfj/FTSE. Terms apply.When investing, your capital is at risk and you may get back less than invested.Past performance doesn't guarantee future results.► Get 15% OFF Finchat.io:Huge thanks to our sponsor, FinChat.io, the best investing toolkit we've discovered! Get 15% off your subscription with code below and unlock powerful tools to analyze stocks, discover hidden gems, and build income streams. Check them out at FinChat.io!https://finchat.io/playingftse/?lmref=iQl2VQ► Episode Notes:What has Steve D done this week? Find out on this week's PlayingFTSE Show!The FTSE 100 is up, the S&P 500 is down. But what have the Steves done?Again it's a mixture of new and old and some new shares for the watch list. And we're really excited about some of the things we've been finding.Nvidia put up another strong result, but the market seemed uninspired. The stock dropped significantly, despite impressive growth in sales and profits. With the next Blackwell already on the way, the shares are now trading at a forward P/E of 21. Is that low enough for one of the Steves to take an interest?Celebrus Technologies is a new stock for us. But Steve W has been looking at it and he very much likes what he sees.It's got good recurring revenues, a price tag that doesn't look too bad – and even a dividend! But will being listed in the UK count against it with investors?Who needs Amazon as a customer? Not Progyny – the reproductive assistance stock has shrugged off the loss of a big customer.It's a setback, but revenues are still growing and the outlook for the company is largely the same (just a year behind). The share price rose then fell – quickly – so is this time to buy?Rolls-Royce is now well past Covid-19 recovery. But the company is still posting strong growth and it's offering impressive guidance for the next few years. The stock climbed 20% on the news, meaning there's a lot priced in. But there are also lots of growth avenues…  Steve D has been looking at Lantheus - a promising healthcare company . It's a stock that's been working higher over the last few years but there could be more to come.Pylarify is the thing investors are typing into Google. But there's a lot more in the pipeline for them to be taking note of over the next few years.Only on this week's PlayingFTSE Podcast!► Support the show:Appreciate the show and want to offer your support? You could always buy us a coffee at: https://ko-fi.com/playingftse(All proceeds reinvested into the show and not to coffee!)There are many ways to help support the show, liking, commenting and sharing our episodes with friends! You can also check out our clothing merch store: https://playingftse.teemill.com/We get a small cut of anything you buy which will be reinvested back into the show...► Timestamps:0:00 INTRO & OUR WEEKS6:36 NVIDIA EARNINGS20:45 CELEBRUS31:09 PROGYNY42:18 ROLLS ROYCE51:21 LANTHEUS► Show Notes:What's been going on in the financial world and why should anyone care? Find out as we dive into the latest news and try to figure out what any of it means. We talk about stocks, markets, politics, and loads of other things in a way that's accessible, light-hearted and (we hope) entertaining. For the people who know nothing, by the people who know even less. Enjoy► Wanna get in contact?Got a question for us? Drop it in the comments below or reach out to us on Twitter: https://twitter.com/playingftseshow Or on Instagram: https://www.instagram.com/playing_ftse/► Enquiries: Please email - playingftsepodcast@gmail(dot)com► Disclaimer: This information is for entertainment purposes only and does not constitute financial advice. Always consult with a qualified financial professional before making any investment decisions.

In this engaging episode, Brian Grawer shares his inspiring journey from being a standout basketball player at the University of Missouri to leading successful sales teams in the highly competitive pharmaceutical industry. With a unique perspective shaped by his athletic background, Brian discusses the parallels between sports and business, offering practical insights into leadership, team building, and personal growth. Brian opens up about the values instilled in him through basketball, such as preparation, discipline, and coachability, and how these lessons have guided him in fostering authentic leadership and cultivating high-performing teams. Whether you're an athlete, a business professional, or a leader looking to inspire your team, this episode is packed with actionable advice and thought-provoking reflections. Our Guest Brian Grawer's leadership journey is rooted in his basketball background.  His father, Rich Grawer, is a decorated Hall of Fame Coach in the state of Missouri. Rich has the 2nd most career wins as the Head Coach at St. Louis University and is still recognized as one of the best basketball minds that has coached at both the high school and collegiate levels.  Brian was a 2x All-Big XII Honorable Mention awarded player from the University of Missouri-Columbia, where he was the starting point guard from 1997-2001. Standing only 5'10”, Brian found ways to be effective and impactful as a “little guy” in a “tall man's game”, through his hard work and mindful approach to the game, his teammates, and his coaches. He ended his career at Mizzou in the top 10 in multiple categories (Steals, 3-pointers made, 3pt %, and Ft %). He held the single-season FT % record (90.5%) for the last 24 years until that record was surpassed in the 2023-24 season at Mizzou.  One of his former coaches, Quin Synder, called Brian, “One of the best leaders he has ever seen.”  After he finished his playing career, Brian spent 3 years as an assistant coach at the college level. He then took his career to the pharmaceutical/Radiopharmaceutical sales path.  Brian is currently the Head of Cardiology Sales at Lantheus, which is a leading radiopharmaceutical-focused company with proven expertise in developing, manufacturing, and commercializing pioneering diagnostic and therapeutic products and artificial intelligence (AI) solutions.  In his 20+ year career in this industry, he has been in numerous different sales roles, both as an individual contributor and as a leader of a team.  Brian has been married to his wife, Angela, for 21 years.  They have two children, Addison (18) and Trent (13).   What You'll Learn in This Episode How preparation, purpose, and passion are the foundation of success The role of coachability in personal and professional growth Insights into transitioning from sports to business leadership Strategies for fostering loyalty and authenticity in teams The importance of self-reflection and vulnerability in leadership How to push yourself and your team out of your comfort zones for growth The parallels between leading on the court and in the boardroom Resources & Links Brian Grawer LinkedIn: https://www.linkedin.com/in/brian-grawer/ Website: www.Lantheus.com Twitter/X: https://x.com/bgrawer?lang=en   Ed Molitor LinkedIn: https://www.linkedin.com/in/themolitorgroup/ Website: https://www.themolitorgroup.com/   Timestamps [00:00:01] Introduction to trust in sales [00:05:12] Lessons learned from a Hall of Fame coaching father [00:12:34] Preparation, purpose, and passion in leadership [00:18:45] The power of coachability and self-reflection [00:25:29] Transitioning from basketball to business [00:30:18] Authentic leadership: Balancing vulnerability and accountability [00:38:45] Building a winning team culture [00:44:10] Advice for emerging leaders [00:50:05] Brian's most memorable basketball and leadership moments    

Life Healthcare R14bn sale of Life Molecular Imaging is the focus of this edition of Business Day Spotlight. Host Mudiwa Gavaza is joined by Peter Wharton-Hood, CEO of Life Healthcare Group. Topics of discussion include: Peter Wharton-Hood outlines the rationale for the transaction; relationship with Lantheus; capital allocation; and investment in technology. Business Day Spotlight is a MultimediaLIVE Production

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Fluid restriction, bed rest, leg compression in acute heart failure Device-detected atrial fibrillation Snapshots  Host: Rick Grobbee Guests: Stephan Achenbach, Carlos Aguiar, Biykem Bozkurt and Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1142 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Biykem Bozkurt has declared to have potential conflicts of interest to report: consulting for Abbott, Abiomed, American Regent, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Daiichi Sankyo, Johnson & Johnson, Lantheus, Liva Nova, Merck, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi-Aventis, Vifor. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Paulus Kirchhof has declared to have potential conflicts of interest to report: fees from AstraZeneca, Roche Diagnostics, Johnson&Johnson, Philips, Medtronic, Boehringer-Ingelheim, Daiichi Sankyo. Research fundings from Sanofi Adventis, Abbott, German Ministry of Education and Research (BMBF), Daiichi Sankyo, British Heart Foundation, Leducq Foundation, European Union horizon2020, UK Medical Research Council and NIHR (UK National Institute of Health Research). Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Jon Denny has been a National Executive Sales and Marketing Recruiter for over 24 years in the Pharmaceutical, Biotech, Medical Devices, and Medical Diagnostics Industries with leading national recruitment firm, Buckman Enochs Coss & Associates (BEC Search). Established in 1979, BEC Search specializes in helping the best Healthcare and Life Science companies find the best people for every level of their organization, Commercial, Med Affairs, Sales, and Marketing Executives - for Projects and Retained. They have partnered with leading companies such as Allergan/Abbvie, Biodesix, Amgen, Apellis, Cardinal Health, Dompe, Genentech, Lantheus, Shionogi, Inc., Supernus Pharmaceuticals, Takeda, Travere Therapeutics, Vertos Medical, and many others.  Before joining BEC, Jon spent over two years in Accounting and Finance Recruitment for a leading staffing firm and 4 years in College/University Recruitment.  In the last two decades, Jon has helped countless individuals in healthcare sales, marketing, and clinical roles find employment opportunities that have been life-changing and he has several current clients he helped early on in their careers. Jon attributes his transformative approach to a unique blend of business acumen, strong work ethic, empathy, and ability to connect with individuals. These traits find their roots in his competitive collegiate athletic background, where he played football for four years at his alma mater, Ohio Northern University. What you'll learn in this episode: The importance of human connection in leadership and recruiting The crucial role of preparation in the recruiting process, for both the candidate and recruiter Reasons why people leave their jobs and how they often relate to issues with management or a lack of development opportunities The impact of a transformational approach in recruitment for greater success How understanding a candidate's story and motivation reveals insights into their suitability The necessity of understanding a candidate's purpose and its connection to career aspirations The high value placed on intangible qualities such as character, integrity, and work ethic in potential hires Additional Resources:  Jon's LinkedIn Jon's Twitter/X  About BEC Search's Website: www.becsearch.com LinkedIn Facebook Instagram Twitter/X Listen to Episode 86 with Jon Denny

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die wachsende Sorge vor Kreditausfällen, Eli Lillys Milliarden-Deal und den Angstmonat Oktober, der seinem Namen mal wieder alle Ehre macht. Außerdem geht es um RWE, E.ON, Zalando, Vonovia, Lyxor US Curve Steepening ETF (WKN: LYX00G), Warner Bros Discovery, Disney, Netflix, BofA, Affirm, Commerzbank, Deutsche Bank, Eli Lilly, Point Biopharma, Novartis, Lantheus, Intel, NextEra Energy, Encavis und iShares Global Green Energy (WKN: A0MW0M). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

The stock market rally generally pulled back modestly Tuesday, but the Nasdaq resisted thanks to megacap leaders. Meritage Homes reclaimed a buy point while Lantheus and Allegro Microsystems flashed early entries, though ALGM stock pared gains significantly.

 The SPDR Regional Banking ETF dropped sharply amid liquidity concerns for PacWest Bancorp and Western Alliance. Volume rose on the NYSE, giving the S&P 500 another distribution day. Shopify and Lantheus were earnings standouts, while gold producer Agnico-Eagle Mines cleared a cup-with-handle base.

The major indexes started strong but finished weak ahead of two-day testimony by Fed chair Powell. The S&P 500 and Nasdaq composite remain above their 21-day moving average lines but the Dow Jones Industrial Average hit resistance at its 50-day line. But there were still pockets of strength including a move above resistance for Splunk, a flat-base breakout by MercadoLibre and a setup continuing for Lantheus.

In this podcast, Dr. Alicia Morgans discusses recent data presented at the 2022 ASCO GU Cancers Symposium, including trials evaluating the use of first-line PARP inhibitors in combination with abiraterone for mCRPC, continuation of enzalutamide after progression, and imaging modalities as predictive and prognostic biomarkers. This activity is available for CE/CME credit. Claim your credit at pce.is/ascogu.Contributors: Dr Morgans has disclosed that she has received funds for research support from Atellas, AstraZeneca, Bayer, Myovant, and Pfizer, and consulting fees from AAA, Astellas, AstraZeneca, Bayer, Blue Earth, Clovis, Dendreon, Janssen, Lantheus, Merck, Myovant, Novartis, Pfizer, Sanofi, and Telix.Ms Martone has no relevant conflicts of interest to report.